Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CSTL
stocks logo

CSTL

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
76.22M
-11.69%
-0.344
-207.42%
75.54M
-14.14%
-0.490
-45.56%
81.88M
-5%
-0.365
-343.33%
Estimates Revision
The market is revising Upward the revenue expectations for Castle Biosciences, Inc. (CSTL) for FY2025, with the revenue forecasts being adjusted by 4.89% over the past three months. During the same period, the stock price has changed by 78.68%.
Revenue Estimates for FY2025
Revise Upward
up Image
+4.89%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-39.28%
In Past 3 Month
Stock Price
Go Up
up Image
+78.68%
In Past 3 Month
Wall Street analysts forecast CSTL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CSTL is 34.39 USD with a low forecast of 23.56 USD and a high forecast of 41.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast CSTL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CSTL is 34.39 USD with a low forecast of 23.56 USD and a high forecast of 41.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 38.630
sliders
Low
23.56
Averages
34.39
High
41.00
Current: 38.630
sliders
Low
23.56
Averages
34.39
High
41.00
Baird
NULL -> Outperform
maintain
$39 -> $41
2025-11-04
Reason
Baird
Price Target
$39 -> $41
2025-11-04
maintain
NULL -> Outperform
Reason
Baird raised the firm's price target on Castle Biosciences to $41 from $39 and keeps an Outperform rating on the shares. The firm updated its model following solid Q3 results and raised revenue outlook.
Scotiabank
Outperform
downgrade
$44 -> $40
2025-05-21
Reason
Scotiabank
Price Target
$44 -> $40
2025-05-21
downgrade
Outperform
Reason
Scotiabank lowered the firm's price target on Castle Biosciences to $40 from $44 and keeps an Outperform rating on the shares. The company raised its full year guidance despite DecisionDx-SCC no longer being reimbursed by Medicare and the discontinuation of IDgenetix, the analyst tells investors. The company remains on track to launch a therapy guidance test for atopic dermatitis by the end of 2025, the firm adds.
Baird
Catherine Ramsey
Buy
Maintains
$36 → $37
2025-02-28
Reason
Baird
Catherine Ramsey
Price Target
$36 → $37
2025-02-28
Maintains
Buy
Reason
Stephens & Co.
Mason Carrico
Buy
Reiterates
$41
2025-01-02
Reason
Stephens & Co.
Mason Carrico
Price Target
$41
2025-01-02
Reiterates
Buy
Reason
Stephens analysts presented the firm's 2025 Best Ideas list, which includes Valley National (VLY), CoStar Group (CSGP), Castle Biosciences (CSTL), Alignment Healthcare (ALHC), Privia Health (PRVA), Vulcan Materials (VMC), South State (SSB), Matson (MATX), Azenta (AZTA), Prog Holdings (PRG), Carvana (CVNA), Blueprint Medicines (BPMC), Truist Financial (TFC), Cognex (CGNX), Fiserv (FI), Hancock Whitney (HWC), SunOpta (STKL), Wingstop (WING), SM Energy (SM), The Andersons (ANDE) and Bank of Marin (BMRC).
See All Ratings

Valuation Metrics

The current forward P/E ratio for Castle Biosciences Inc (CSTL.O) is -26.22, compared to its 5-year average forward P/E of -19.92. For a more detailed relative valuation and DCF analysis to assess Castle Biosciences Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-19.92
Current PE
-26.22
Overvalued PE
4.25
Undervalued PE
-44.10

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-15.68
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
2.30
Undervalued EV/EBITDA
-33.65

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
6.21
Current PS
0.00
Overvalued PS
12.38
Undervalued PS
0.04
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

CSTL News & Events

Events Timeline

(ET)
2025-12-12
07:10:00
Castle Biosciences Publishes Study Confirming TissueCypher Test Validity
select
2025-12-09 (ET)
2025-12-09
07:20:00
Castle Biosciences Publishes Expert Consensus Paper Supporting DecisionDx-Melanoma Test
select
2025-11-14 (ET)
2025-11-14
07:10:00
Castle Biosciences Reveals Updated Findings on DecisionDx-Melanoma Test
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
3.5
12-12Globenewswire
Castle Biosciences Publishes Study Validating TissueCypher Test for Barrett's Esophagus Risk Stratification
  • Risk Identification Capability: The newly published systematic review and meta-analysis demonstrates that the TissueCypher test can identify high-risk patients, who are 6.7 times more likely to progress to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC) within five years compared to low-risk patients, significantly enhancing clinical decision-making precision.
  • Clinical Confidence in Application: High-risk patients exhibit an annual progression rate of 5.6%, while low-risk patients have a rate of only 1.7%, indicating that the TissueCypher test can assist physicians in formulating more effective personalized monitoring and intervention strategies, thereby improving patient outcomes.
  • Data Integration Advantage: This meta-analysis consolidates data from six studies, confirming the consistency and reproducibility of TissueCypher across different types of Barrett's esophagus patients, further solidifying its clinical value as a risk stratification tool.
  • Innovative Medical Tool: TissueCypher, as a precision medicine test, has been validated in biopsies from over 8,000 patients, demonstrating its potential in early identification and management of high-risk patients, which can reduce unnecessary medical procedures and enhance treatment efficacy.
[object Object]
Preview
3.5
12-12Newsfilter
Castle Biosciences Publishes Study Validating TissueCypher Test's Risk Stratification Capabilities
  • Risk Identification Capability: The newly published systematic review and meta-analysis demonstrate that the TissueCypher test can increase the identification rate of high-risk patients by 6.7 times, significantly outperforming traditional pathology methods, thereby enabling more effective personalized management by physicians.
  • Clinical Validation: The study consolidates data from six studies, confirming TissueCypher's consistency and reproducibility in identifying high-risk patients, which enhances its clinical value as a risk stratification tool.
  • Progression Rate Analysis: High-risk patients exhibit an annual progression rate of 5.6%, significantly higher than the 1.7% rate for low-risk patients, providing strong evidence for clinical intervention and helping physicians formulate more effective treatment plans.
  • Personalized Care: By accurately identifying truly high-risk patients, TissueCypher not only boosts confidence in early intervention but also reduces unnecessary procedures for low-risk patients, optimizing the allocation of healthcare resources.
[object Object]
Preview
3.5
12-09Newsfilter
Castle Biosciences Publishes Expert Consensus on 31-Gene Test for Melanoma
  • Expert Consensus Release: Castle Biosciences' publication endorses the DecisionDx-Melanoma test, highlighting its significance in managing melanoma patients, which may enhance survival rates and personalized treatment outcomes.
  • Clinical Utility Validation: The test is supported by a comprehensive review of 26 studies involving over 7,500 patients, providing prognostic information independent of traditional clinicopathologic factors, thereby optimizing clinical decision-making and improving patient risk assessment accuracy.
  • Risk Stratification Capability: The expert panel unanimously agreed that DecisionDx-Melanoma should be used in earlier-stage patients to identify those needing escalated care and to guide sentinel lymph node biopsy decisions in T1b-T3 tumors, enhancing the scientific basis for clinical management.
  • Integration with Existing Systems: Integrating DecisionDx-Melanoma results with the AJCC 8th Edition staging system significantly enhances prognostic precision, aiding in the identification of low-risk patients and potentially reducing unnecessary surgical interventions.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Castle Biosciences Inc (CSTL) stock price today?

The current price of CSTL is 38.63 USD — it has increased 1.74 % in the last trading day.

arrow icon

What is Castle Biosciences Inc (CSTL)'s business?

Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers five commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology and ophthalmology. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for use in patients with cutaneous squamous cell carcinoma (SCC). It also focused on chronic acid reflux related diseases, including esophageal cancer.

arrow icon

What is the price predicton of CSTL Stock?

Wall Street analysts forecast CSTL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CSTL is 34.39 USD with a low forecast of 23.56 USD and a high forecast of 41.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Castle Biosciences Inc (CSTL)'s revenue for the last quarter?

Castle Biosciences Inc revenue for the last quarter amounts to 83.04M USD, decreased -3.19 % YoY.

arrow icon

What is Castle Biosciences Inc (CSTL)'s earnings per share (EPS) for the last quarter?

Castle Biosciences Inc. EPS for the last quarter amounts to -0.02 USD, decreased -125.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Castle Biosciences Inc (CSTL)'s fundamentals?

The market is revising Upward the revenue expectations for Castle Biosciences, Inc. (CSTL) for FY2025, with the revenue forecasts being adjusted by 4.89% over the past three months. During the same period, the stock price has changed by 78.68%.
arrow icon

How many employees does Castle Biosciences Inc (CSTL). have?

Castle Biosciences Inc (CSTL) has 761 emplpoyees as of December 13 2025.

arrow icon

What is Castle Biosciences Inc (CSTL) market cap?

Today CSTL has the market capitalization of 1.13B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free